PharmaShots | Incisive News in 3 Shots

Subscribe Now

Kyverna Therapeutics

Kyverna Therapeutics Enters into a Collaboration Agreement with Stanford University to Evaluate KYV-101 for the Treatment of Multiple Sclerosis

Kyverna Therapeutics Enters into a Collaboration Agreement with Stanford University to Evaluate KYV-101 for the Treatment of Multi...

March 8, 2024

PharmaShots Weekly Snapshots (October 09–13, 2023) _

PharmaShots Weekly Snapshots (October 09–13, 2023) _

October 14, 2023

Kyverna Therapeutics Receives the US FDA’s IND Clearance to Initiate the P-I/II Study of KYV-101 for the Treatment of Scleroderma

Kyverna Therapeutics Receives the US FDA’s IND Clearance to Initiate the P-I/II Study of KYV-101 for the Treatment of Scleroderma

October 13, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us